A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma.
about
Hepatocellular carcinoma: Will novel targeted drugs really impact the next future?Pharmacological modulation of cell death in organ transplantation.Down-regulation of UBC9 increases the sensitivity of hepatocellular carcinoma to doxorubicin.Death Receptors: New Opportunities in Cancer Therapy.Can smart nanomedicine deliver effective targeted cytotoxic treatments to hepatocellular carcinomas while reducing the liver damage?Developing TRAIL/TRAIL death receptor-based cancer therapies.Suppression of SOCS3 enhances TRAIL-induced cell growth inhibition through the upregulation of DR4 expression in renal cell carcinoma cells
P2860
Q26741201-282C9F1D-368F-406A-A29E-596ED499CE95Q39290025-A7C3AC4C-2658-4F53-AFFE-1103ACCFE0FBQ41472744-C8F694F5-3D99-462D-BC39-FC62B7F6778DQ47108799-32AE70B0-5591-4C96-AB10-64E8B29DD658Q50095663-979202F6-8155-491C-A47C-3BA0265CAEA3Q53701901-C6B414E0-3619-4F95-86FD-9BC08E8B15EEQ58801106-D254B05C-9358-450D-8B47-D377B7563177
P2860
A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
A randomized, double-blind, pl ...... nced hepatocellular carcinoma.
@en
type
label
A randomized, double-blind, pl ...... nced hepatocellular carcinoma.
@en
prefLabel
A randomized, double-blind, pl ...... nced hepatocellular carcinoma.
@en
P2093
P2860
P50
P356
P1433
P1476
A randomized, double-blind, pl ...... anced hepatocellular carcinoma
@en
P2093
B Giantonio
D Lungulescu
M Rodriguez-Torres
R Humphreys
R N Kalyani
P2860
P304
P356
10.1093/ANNONC/MDW004
P577
2016-01-22T00:00:00Z